logo
logo
IRTC stock ticker logo

iRhythm Technologies, Inc.

NASDAQ•IRTC
CEO: Mr. Quentin S. Blackford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2016-10-20
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Contact Information
699 8th Street, Suite 600, San Francisco, CA, 94103, United States
415-632-5700
www.irhythmtech.com
Market Cap
$3.65B
P/E (TTM)
-81.8
26.6
Dividend Yield
--
52W High
$212.00
52W Low
$92.52
52W Range
17%
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$208.89M+0.00%
4-Quarter Trend

EPS

$0.17+0.00%
4-Quarter Trend

FCF

$14.49M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Net revenue reached $747.1M USD, marking 26% increase driven by higher service volumes and Zio AT adoption.
Gross Profit Margin Expansion Gross profit reached $527.3M USD, showing 29% growth due to better pricing and volume mix.
Net Loss Significantly Reduced Net loss narrowed to $(44.6)M USD, reflecting a substantial 61% reduction compared to prior year.
IPR&D Expense Reverts Acquired IPR&D expense dropped 91% to $3.0M USD following 2024 BioIntelliSense license charge.

Risk Factors

Medicare Reimbursement Risk Reimbursement highly regulated; failure to comply with remote test rules risks penalties and revenue loss.
Competitive Monitoring Market Remote monitoring market is highly competitive; competitors developing more effective devices could reduce opportunities.
Significant Debt Load Servicing $661.3M USD in 2029 Notes requires substantial cash flow, impacting future financial flexibility.
Ongoing Legal Proceedings Company faces ongoing patent litigation risks; adverse outcomes could result in damages or prohibit product use.

Outlook

Expand Core Monitoring Market Strategy focuses on penetrating core market, expanding utilization across cardiology and primary care specialties.
Adjacent Clinical Opportunities Pursuing proactive monitoring in adjacent areas like Sleep Apnea and Heart Failure using existing platform capabilities.
Advance Product Portfolio Investing in next-gen MCT device, 510(k) submitted Q3 2025, enhancing detection algorithms and insights.
International Expansion Focus Selectively expanding internationally in geographies with established regulatory pathways and reimbursement progression.

Peer Comparison

Revenue (TTM)

OSCR stock ticker logoOSCR
$11.70B
+27.5%
BLCO stock ticker logoBLCO
$5.10B
+6.5%
BRKR stock ticker logoBRKR
$3.44B
+2.1%

Gross Margin (Latest Quarter)

ARWR stock ticker logoARWR
100.0%
+50.6pp
AXSM stock ticker logoAXSM
93.7%
+1.1pp
GKOS stock ticker logoGKOS
83.8%
+1.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
AXSM$7.98B-43.1-254.1%35.0%
PCVX$7.86B-9.7-25.9%7.5%
ARWR$7.71B38.136.1%19.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
9.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:Apr 29, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data